• Mon. Feb 6th, 2023



Genetron Health Joins Major R&D Project Led by the Ministry of Science and Technology in China for Early Screening of Lung and

Genetron Health Joins Major R&D Project Led by the Ministry of Science and
Technology in China for Early Screening of Lung and Digestive System Cancers

BEIJING, Aug. 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited
(“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision
oncology platform company in China that specializes in offering molecular
profiling tests, today announced its participation in the launch of a major
national research project for early screening of lung and digestive system
cancers led by China’s Ministry of Science and Technology (“MOST”).

Based on the Company’s proprietary technology, Mutation Capsule^TM, Genetron
Health is collaborating with the National Cancer Center and the Cancer
Hospital, Chinese Academy of Medical Sciences (“CAMS”) for the second time, to
provide key technological contributions for the "Liquid Biopsy-based Malignant
Tumor Early Screening Technology Research and Development Project”. The launch
meeting for the project was held in Beijing on August 29.

At the meeting, representing Genetron Health was Sizhen Wang, the Company’s
co-founder and CEO. Other attendees at the event included Jie He, Academician
of Chinese Academy of Sciences, Director of National Cancer Center and
President of Cancer Hospital, CAMS; Jie Wang, Director of Department of
Oncology, Cancer Hospital, CAMS; and Qian Liu, professor at the Cancer
Hospital, CAMS.

The project’s goal is to achieve a breakthrough in the key technologies of
liquid biopsy for cancer screening. Under this premise, the project targets to
build a highly sensitive, highly specific, efficient and affordable liquid
biopsy-based early detection technology platform, and develop proprietary
cancer screening and early detection tests. The project will focus on lung and
digestive system cancers, and is designed to include a multi-center,
prospective cohort study in lung cancer of 120,000 high-risk individuals in 20
provinces, as well as a cohort study in digestive system cancer of more than
100,000 patients in urban areas in China. Currently, Genetron Health is the
only company in China participating in national key research and development
projects organized by the Ministry of Science and Technology for liver, lung
and digestive cancer early screening.

“Cancer has become the leading cause of death in China and is a serious threat
to people’s health and lives, yet most patients who seek treatment are already
at a terminal stage,” said Jie He. “The 2019 government work report expresses
the need to promote early screening, early detection and treatment, and
scientific research on cancers, aiming at solving this critical problem of
people’s livelihood. The launch of this project indicates that preventative
screening and early detection of cancers has become a major research and
development direction for the Ministry of Science and Technology, and it is
also part of the national strategy. We hope to increase the depth, prevalence
and practicability of cancer early screening, early detection and treatment
research to benefit cancer patients.”

“Early detection and treatment are the most effective ways to improve clinical
outcomes in cancer patients. We choose to partner with Genetron Health for its
leading technology capabilities and we expect to develop a proprietary
malignant tumor screening and early detection testing kit and implement into
clinical use to significantly improve the cure rates of these types of cancer
for our citizens,” said Jie Wang.

“The importance of early cancer screening cannot be overemphasized. However,
existing examinations lack precise and high-quality tumor screenings and only
use a single biomarker target. Early cancer diagnosis and screening generally
does not meet the standard of specificity and sensitivity, which will mislead
patients. With this national research project, we hope to achieve technology
breakthroughs and move past the challenges of current clinical screenings,”
said Qian Liu.

Genetron Health, as a leading innovator in the field of early cancer screening
in China, plans to adopt its self-developed Mutation Capsule^TM technology for
this project. Mutation Capsule^TM requires only a small amount of blood to
simultaneously detect methylation and several types of ctDNA alternations
including SNV, Indel, CNV, etc. This will allow multiple tests to be performed
on one sample without sacrificing sensitivity. The Mutation Capsule technology
has shown high sensitivity and specificity preliminary data in the early
screening study of liver cancer.

“We are honored to be involved in this major government-led project based on
our Mutation Capsule^TM technology, which highlights our technological
strength in cancer early screening. In addition, we are delighted that we are
able to apply this technology beyond liver cancer and now into lung and
digestive system cancers,” said Sizhen Wang. “We will continue to expand our
early screening research into more types of cancer and to accelerate the
clinical development and commercialization effort. Our goal is to develop
tests with high performance and affordable pricing in order to reduce
cancer-related healthcare expenses in our country, and more importantly, to
save more lives.”

About Genetron Health Early Screening for Liver Cancer
In March 2019, Genetron Health, in collaboration with the National Cancer
Center and the Cancer Hospital, CAMS, deployed Mutation Capsule^TM technology
to complete a prospective cohort study in liver cancer early screening (the
HCCscreen^TM) on hepatitis B virus carriers using cell free DNA (cfDNA) and
protein markers. Results were published in Proceedings of the National Academy
of Sciences (PNAS), cited in the Guidelines for Diagnosis and Treatment of
Primary Liver Cancer (2019 edition) issued by the National Health Commission,
and Genetron Health was approved to join a Major National Science and
Technology Project by MOST.

Genetron Health has since continued to optimize the Mutation Capsule^TM
platform and liver early screening test in its ongoing cohort study with 4,500
HBsAg+ individuals. Preliminary data from 297 patients at one center
demonstrated over 92% sensitivity, 93% specificity and a 35% positive
predictive value.

About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH)is
a leading precision oncology platform company in China that specializes in
cancer molecular profiling and harnesses advanced technologies in molecular
biology and data science to transform cancer treatment. The Company has
developed a comprehensive oncology portfolio that covers the entire spectrum
of cancer management, addressing needs and challenges from early screening,
diagnosis and treatment recommendations, as well as continuous disease
monitoring and care. Genetron Health also partners with global
biopharmaceutical companies and offers customized services and products. For
more information, please visit ir.genetronhealth.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of
federal securities laws, including statements regarding the potential benefits
and advantages of Genetron Health’s Mutation Capsule™ technology, which
involve risks and uncertainties that could cause the actual results to differ
materially from the anticipated results and expectations expressed in these
forward-looking statements. These statements are made under the “safe harbor”
provisions of the U.S. Private Securities Litigation Reform Act of 1995.
Statements that are not historical facts, including statements about the
Company’s beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and uncertainties, and a
number of factors could cause actual results to differ materially from those
contained in any forward-looking statement. In some cases, forward-looking
statements can be identified by words or phrases such as “may”, “will,”
“expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,”
“believe,” “potential,” “continue,” “is/are likely to” or other similar
expressions. Further information regarding these and other risks,
uncertainties or factors is included in the Company’s filings with the SEC.
All information provided in this press release is as of the date of this press
release, and the Company does not undertake any duty to update such
information, except as required under applicable law.

Investor Relations Contacts
Hoki Luk
Head of Investor Relations
Email: hoki.luk@genetronhealth.com
Phone: +1 (408) 204-5343

Stephanie Carrington
Westwicke, an ICR Company
Email: Stephanie.Carrington@westwicke.com
Phone: +1 (646) 277-1282

Bill Zima
ICR, Inc.
Email: bill.zima@icrinc.com

Media Relations Contact
Edmond Lococo
Mobile: +86 138-1079-1408



Source Article